Skip to content

A prospective randomized controlled clinical study on the efficacy of salvia miltiorrhiza and fibroblast growth factor paste and Triamcinolone Acetonide Acetate and Salvia miltiorrhiza solution injection in the treatment of oral submucous fibrosis

A prospective randomized controlled clinical study on the efficacy of salvia miltiorrhiza and fibroblast growth factor paste and Triamcinolone Acetonide Acetate and Salvia miltiorrhiza solution injection in the treatment of oral submucous fibrosis

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200065845
Enrollment
Unknown
Registered
2022-11-16
Start date
2022-11-17
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral Submucous Fibrosis

Interventions

The group of Salvia miltiorrhiza paste application:Application of salvia miltiorrhiza paste and fibroblast growth factor on oral lesions of patients with oral submucous fibrosis
The group of Triamcinolone Acetonide Acetate and Salvia miltiorrhiza injection:Injection of triamcinolone acetonide acetate and Salvia miltiorrhiza into the oral lesions of patients with oral submucou

Sponsors

Hunan Xiangya Stomatological Hospital of Central South University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients aged > 18 years; 2. Patients with oral submucous fibrosis; 3. Patients who signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. People who are allergic to triamcinolone acetonide, salvia miltiorrhiza and bovine basic fibroblast growth factor gel; 2. Pregnant women and lactating women; 3. Those who have used immunomodulator and hormone drugs within three months; 4. People with mental illness or cognitive dysfunction; 5. Those who can not take medicine according to the doctor's advice and return on time; 6. People with other local or systemic diseases; 7. Patients participating in other clinical trials; 8. The researcher thinks that other reasons are not suitable for the clinical trial.

Design outcomes

Primary

MeasureTime frame
Mouth opening;Burning sensation;Tongue protrusion;Cheek flexibility;Color and lustre of mucous membrane;

Countries

China

Contacts

Public ContactChen Jun

Hunan Xiangya Stomatological Hospital of Central South University

chenjun1222@csu.edu.cn+86 15116333525

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026